The 23 references in paper S. Zyryanov K., K. Zatolochina E., V. Cheltsov V., С. Зырянов К., К. Затолочина Э., В. Чельцов В. (2017) “Возможна ли взаимозаменяемость лекарственных препаратов для ингаляционного применения? // Could inhalational drugs be interchangeable?” / spz:neicon:pulmonology:y:2017:i:4:p:529-536

1
Зырянов С.К., Айсанов З.Р. Воспроизведенные ингаляционные лекарственные средства: как оценить их свойства? Пульмонология. 2012; (3): 115–118. DOI: 10. 18093/0869-0189-2012-0-3-115-118.
(check this in PDF content)
2
Daley-Yates P.T., Parkins D.A. Establishing bioequivalence for inhaled drug; weighing the evidence.Expert Opin. Drug Deliv.2011; 8 (10): 1297–1308. DOI: 10.1517/17425247. 2011.592827.
(check this in PDF content)
3
European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on the requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of asthma and chronic obstructive pulmonary disease (COPD) in adults and for use in the treatment of asthma in children and adolescents. Doc. Ref. CPMP/EWP/4151/00 Rev. 1. 2009. London, 22 January, 2009. Available at: http://www.ema.europa.eu/docs/en_ GB/document_library/Scientific_guideline/2009/09/ WC500003504.pdf
(check this in PDF content)
4
Price D., Haughney J., Sims E. et al. Effectiveness of inhaler types for real-world asthma management: retrospective observational study using the GPRD. J. Asthma Allergy. 2011; 4: 37–47. DOI: 10.2147/JAA.S17709.
(check this in PDF content)
5
Newman S.P. Principles of metered-dose inhaler design. Respir. Care. 2005; 50 (9): 1177–1190.
(check this in PDF content)
6
Hochrainer D., Hölz H., Kreher C. et al. Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers.J. Aerosol. Med.2005; 18 (3): 273–282. DOI: 10.1089/jam. 2005.18. 273.
(check this in PDF content)
7
Ninbovorl J., Sawatdee S., Srichana T. Factor affecting the stability and performance of ipratropium bromide; fenoterol hydrobromide pressurized-metered dose inhalers. AAPS PharmSci'Tech.2013; 14 (4): 1294–1302. DOI: 10.1208/ s12249-013-0024-4.
(check this in PDF content)
8
Скачилова С.Я., Чучалин А.Г., Шилова Е.В. и др. Факторы, влияющие на респирабельную фракцию ингаляционных противоастматических препаратов. Разра' ботка и регистрация лекарственных средств. 2013; (2): 41–45.
(check this in PDF content)
9
Berger W. Aerosol devices and asthma therapy. Curr. Drug Deliv. 2009; 6 (1): 38–49.
(check this in PDF content)
10
Lenney J., Innes J.A., Crompton G.K. Inappropriate inhaler use: assessment of use and patient preference of seven inhalation devices. EDICI. Respir. Med. 2000; 94 (5): 496–500.
(check this in PDF content)
11
Giraud V., Roche N. Misuse of corticosteroid meter-dose inhaler is associated with decrease asthma stability. Eur. Respir. J.2002; 19 (2): 246–251.
(check this in PDF content)
12
Nimmo C.J., Chen D.N., Martinusen S.M. et al. Assessment of patient acceptance and inhalation technique of a pressurized aerosol inhaler and two breath-actuated devices.Ann. Pharmacother.1993; 27 (7–8): 922–927. DOI: 10.1177/106002809302700721.
(check this in PDF content)
13
Usmani O.S., Biddiscombe M.F., Barnes P.J. Regional lung deposition and bronchodilator response as a function of beta2agonist particle size. Am. J. Respir. Crit. Care Med. 2005, 172 (12): 1497–1504. DOI: 10.1164/rccm.200410-1414OC.
(check this in PDF content)
14
Степанян И.Э. Спирива Респимат – препарат нового поколения. Русский медицинский журнал. 2012; 20 (6): 324–328.
(check this in PDF content)
15
Laube B.L., Janssens H.M., de Jongh F.H et al. What the pulmonary specialist should know about the new inhalation therapies. Eur. Respir. J.2011; 37 (6): 1308–1331. DOI: 10.1183/09031936.00166410.
(check this in PDF content)
16
Архипов В.В., Архипова Д.Е., Лазарева Н.Б. Новые ингаляционные устройства для терапии хронической обструктивной болезни легких. Пульмонология. 2016; 26 (3): 352–356. DOI: 10.18093/0869-0189-2016-26-3352-356.
(check this in PDF content)
17
Patton J.S., Byron P.R. Inhaling medicines: delivering drugs to the body through the lungs. Nat. Rev. Drug Discov. 2007; 6 (1): 67–74. DOI: 10.1038/nrd2153.
(check this in PDF content)
18
Lawrence M., Wolfe J., Webb D.R. et al. Efficacy of inhaled fluticasone propionate in asthma results from topical and not from systemic activity. Am. J. Respir. Crit. Care Med.
(check this in PDF content)
19
7; 156: 744–751. 19. Clearie K.I., Williamson P.A., Vaidyanathan S. et al. Systemic bioavailability of hydrofluoroalkane formulation of fluticasone/salmeterol in healthy volunteers via pMDI alone and spacer. Br. J. Clin. Pharmacol.2010; 69 (6): 637–644. DOI: 10.1111/j.1365-2125.2010.03655.x.
(check this in PDF content)
20
Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Revised 2017. Available at: www.goldcopd.com
(check this in PDF content)
21
Tashkin D.P., Celli B., Senn S. et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med.2008; 359 (15): 1543–1554. DOI: 10. 1056/NEJMoa0805800.
(check this in PDF content)
22
Bateman E.D., Tashkin D., Siafakas N. et al. A one-year trial of tiotropium Respimat plus usual therapy in COPD patients. Respir. Med.2010; 104 (10): 1460–1472. DOI: 10.1016/j.rmed.2010.06.004.
(check this in PDF content)
23
Пастернак Е.Ю., Затолочина К.Э., Аляутдин Р.Н. и др. Метод спонтанных сообщений как инструмент контроля взаимозаменяемых лекарственных препаратов в условиях их широкого применения. Врач.2016; 9: 2–5. Поступила 08.08.17
(check this in PDF content)